Chemotherapy by the intravenous and intraperitoneal routes combined in ovarian cancer. 1990

B Zylberberg, and J H Ravina, and J Salat-Baroux, and P Madelenat, and D Zarca, and D Dormont
Obstetrics and Gynaecology Department, Hôpital Tenon, Paris, France.

Intraperitoneal (ip) administration allows delivery of concentrations of cytotoxic drugs to the site of tumor development that could not be attained by the intravenous (iv) route. Rather than leaving ip delivery systems (Tenckhoff catheter, Port à Cath, etc.) in position for several months, with the attendant risk of complications, we prefer to use a simple needle for lumbar puncture and leave it in place between 1 and 2 hr at each infusion of chemotherapy. Results observed at second-look laparotomy in 31 patients with stage III (FIGO) common epithelial carcinoma, treated from January 1980 to December 1986, are reported after six to ten courses of ip and iv chemotherapy combined. In five patients in whom complete surgical excision had been possible, there was still complete remission (CR). In 26 patients in whom initial surgical excision had been incomplete, there was complete remission in 20 (76%). In the other 6 cases, there were small residual masses (incomplete remission), which could readily be excised by the surgeon. Following second-look laparotomy, these 6 patients received ip maintenance chemotherapy for a further 6 months. During follow-up periods of 22 to 105 months (average 45 months), 8 recurrences were observed (4 of them died); 23 of 31 patients are disease free. At 4 years, actuarial survival was 81.5% and actuarial disease-free survival was 66.2%.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007813 Laparotomy Incision into the side of the abdomen between the ribs and pelvis. Minilaparotomy,Laparotomies,Minilaparotomies
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000267 Tissue Adhesions Pathological processes consisting of the union of the opposing surfaces of a wound. Adhesions, Tissue,Surgery-Induced Tissue Adhesions,Surgical Adhesions,Adhesion, Surgery-Induced Tissue,Adhesion, Surgical,Adhesion, Tissue,Adhesions, Surgery-Induced Tissue,Adhesions, Surgical,Surgery Induced Tissue Adhesions,Surgery-Induced Tissue Adhesion,Surgical Adhesion,Tissue Adhesion,Tissue Adhesion, Surgery-Induced,Tissue Adhesions, Surgery-Induced

Related Publications

B Zylberberg, and J H Ravina, and J Salat-Baroux, and P Madelenat, and D Zarca, and D Dormont
September 1988, Hematology/oncology clinics of North America,
B Zylberberg, and J H Ravina, and J Salat-Baroux, and P Madelenat, and D Zarca, and D Dormont
October 2010, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
B Zylberberg, and J H Ravina, and J Salat-Baroux, and P Madelenat, and D Zarca, and D Dormont
September 2007, Gynecologie, obstetrique & fertilite,
B Zylberberg, and J H Ravina, and J Salat-Baroux, and P Madelenat, and D Zarca, and D Dormont
April 2000, Cancer treatment reviews,
B Zylberberg, and J H Ravina, and J Salat-Baroux, and P Madelenat, and D Zarca, and D Dormont
January 2017, European journal of gynaecological oncology,
B Zylberberg, and J H Ravina, and J Salat-Baroux, and P Madelenat, and D Zarca, and D Dormont
January 2020, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
B Zylberberg, and J H Ravina, and J Salat-Baroux, and P Madelenat, and D Zarca, and D Dormont
September 2015, Harefuah,
B Zylberberg, and J H Ravina, and J Salat-Baroux, and P Madelenat, and D Zarca, and D Dormont
January 2008, Advances in experimental medicine and biology,
B Zylberberg, and J H Ravina, and J Salat-Baroux, and P Madelenat, and D Zarca, and D Dormont
July 2012, Oncology nursing forum,
B Zylberberg, and J H Ravina, and J Salat-Baroux, and P Madelenat, and D Zarca, and D Dormont
November 2003, Current oncology reports,
Copied contents to your clipboard!